Alpha-synuclein and Parkinson disease

被引:1
|
作者
Hui Liu1
机构
关键词
α-synuclein; Parkinson’s disease; Lewy’s body;
D O I
暂无
中图分类号
R742.5 [震颤麻痹综合征];
学科分类号
1002 ;
摘要
OBJECTIVE:To review the recent progresses on the studies ofα-synuclein in the pathogenesis of Parkinson disease(PD)and look into the perspective ofα-synuclein as a new therapy target.DATA SOURCES:To search the literatures on the progresses of PD studies,especially on the structure,gene expression of α-synuclein and the pathogenesis of PD in Medline from January 1998 to February 2007.Search terms were “Parkinson’s disease,α-synuclein” in English.STUDY SELECTION:Initial check the data and choose the original and review articles directly linked to the role of α-synuclein in PD pathogenesis and screening out indirectly discussing articles.Collect the full text and trace the quoting articles and the quoted articles.Only the latest reviews were chosen in Chinese articles.DATA EXTRACTION:There were 424 articles on α-synuclein and its role in the pathogenesis of PD and 43 articles directly related withα-synuclein were chosen among which 12 were reviews.DATA SYNTHESIS:α-synuclein is a kind of soluble protein expressed in pre-synapse in central nervous system encoded by gene in homologous chromosome 4q21.It has physiological function in modulating the stability of membrane and neural plasticity.There is a close relationship between gene mutation inα-synuclein and the pathogenesis of PD.Environmental and genetic factors can induce the misfolding ofα-synuclein,and secondary structural change can result in oligomer formation which induces a series of cascade reaction to damage dopaminergic system subsequently.Cell and animal transgenic and non-transgenic models are established recently and the important role of α-synuclein in the pathogenesis both of familial and sporadic PD is confirmed.Studies reveal that inhibiting the aggregation of α-synuclein can prevent its neurotoxicity;gene parkin can intercept the cell death pathway triggered by the aggregation ofα-synuclein in cytoplasm.CONCLUSION:Gene mutation ofα-synuclein and the impairment in its structure and function are importan in the pathogenesis of PD.Intervention of the gene mutations and abnormal protein aggregation ofα-synuclein may be a new strategy for preventing and treating PD.
引用
收藏
页码:239 / 243
页数:5
相关论文
共 50 条
  • [21] Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease
    Fields, Carroll Rutherford
    Bengoa-Vergniory, Nora
    Wade-Martins, Richard
    [J]. FRONTIERS IN MOLECULAR NEUROSCIENCE, 2019, 12
  • [22] Parkinson's Disease, Cortical Dysfunction, and Alpha-Synuclein
    Caviness, John N.
    Lue, Lih-Fen
    Beach, Thomas G.
    Hentz, Joseph G.
    Adler, Charles H.
    Sue, Lucia
    Sadeghi, Ramin
    Driver-Dunckley, Erika
    Evidente, Virgilio G.
    Sabbagh, Marwan N.
    Shill, Holly A.
    Walker, Douglas G.
    [J]. MOVEMENT DISORDERS, 2011, 26 (08) : 1436 - 1442
  • [23] Sumoylation of alpha-synuclein in the pathogenesis of parkinson's disease
    Engelender, S.
    [J]. JOURNAL OF NEUROCHEMISTRY, 2019, 150 : 48 - 48
  • [24] Autoantibodies to alpha-synuclein in inherited Parkinson's disease
    Papachroni, Katerina K.
    Ninkina, Natalia
    Papapanagiotou, Angeliki
    Hadjigeorgiou, Georgios M.
    Xiromerisiou, Georgia
    Papadimitriou, Alexandros
    Kalofoutis, Anastasios
    Buchman, Vladimir L.
    [J]. JOURNAL OF NEUROCHEMISTRY, 2007, 101 (03) : 749 - 756
  • [25] Familial Parkinson's disease - The awakening of alpha-synuclein
    Goedert, M
    [J]. NATURE, 1997, 388 (6639) : 232 - 233
  • [26] The central role of alpha-synuclein in Parkinson's disease
    Halliday, G.
    [J]. JOURNAL OF NEUROCHEMISTRY, 2015, 134 : 54 - 54
  • [27] Lymphomonocyte alpha-synuclein levels in aging and in Parkinson disease
    Brighina, Laura
    Prigione, Alessandro
    Begni, Barbara
    Galbussera, Alessio
    Andreoni, Simona
    Piolti, Roberto
    Ferrarese, Carlo
    [J]. NEUROBIOLOGY OF AGING, 2010, 31 (05) : 884 - 885
  • [28] Targeting Alpha-Synuclein for the Treatment of Parkinson's Disease
    Rohn, Troy T.
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2012, 11 (02) : 174 - 179
  • [29] Alpha-synuclein and the Parkinson's disease drug pipeline
    Espay, Alberto J.
    McFarthing, Kevin
    [J]. PARKINSONISM & RELATED DISORDERS, 2023, 111
  • [30] Role of alpha-synuclein and tau in Parkinson's disease
    Trojanowski, JQ
    [J]. MOVEMENT DISORDERS, 2004, 19 : S2 - S2